Sandoz Group (OTCMKTS:SDZNY) Hits New 52-Week High - Here's What Happened

Key Points

• Sandoz Group AG shares hit a new 52-week high at $61.58, marking a significant increase from the previous closing price of $55.91.
• Royal Bank of Canada upgraded Sandoz Group's rating from "hold" to a "moderate buy," indicating positive sentiment among analysts.
• The company specializes in developing and marketing generic pharmaceuticals and biosimilars across various therapeutic areas including oncology, diabetes, and immunology.

Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY - Get Free Report) reached a new 52-week high during trading on Thursday . The stock traded as high as $61.58 and last traded at $61.58, with a volume of 4017 shares changing hands. The stock had previously closed at $55.91.

Analyst Ratings Changes

Separately, Royal Bank Of Canada upgraded shares of Sandoz Group from a "hold" rating to a "moderate buy" rating in a research report on Friday, May 2nd.

Sandoz Group Price Performance

The company has a debt-to-equity ratio of 0.57, a current ratio of 1.24 and a quick ratio of 0.79. The business has a 50 day moving average of $54.88 and a 200 day moving average of $47.92.

About Sandoz Group

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.